Gambogenic acid-induced time- and dose-dependent growth inhibition and apoptosis involving Akt pathway inactivation in U251 glioblastoma cells

Journal of Natural Medicines

Volumn 66, Issue 1, 2012, Pages 62-69

  Chen, Hong Bo ^a   Zhou, Lan Zhen ^b   Mei, Lin ^a   Shi, Xiao Jun ^a   Wang, Xiao Shan ^b   Li, Qing Lin ^b   Huang, Laiqiang ^a  

^a TSINGHUA UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Akt pathway; Apoptosis; Cell cycle; Gambogenic acid; Glioblastoma multiforme

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CASPASE; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMBOGENIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TIME; TRADITIONAL MEDICINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRAIN NEOPLASMS; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GARCINIA; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TERPENES; TIME FACTORS; XANTHONES;

EID: 84856224689     PISSN: 13403443     EISSN: 18610293     Source Type: Journal    
DOI: 10.1007/s11418-011-0553-7     Document Type: Article

References (28)

1. Panthong A, Norkaew P, Kanjanapothi D, Taesotikul T, Anantachoke N, Reutrakul V (2008) Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f. J Ethnopharmacol 111:335-340
2. Zhang HZ, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, Drewe J, Cai SX (2004) Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 12:309-317 (Pubitemid 38064204)
3. Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang Y, Zhang HW, Tan Z, Wang X (2007) Gambogic acid-induced G2/M phase cellcycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28:632-638 (Pubitemid 46523358)
4. Lu GB, Yang XX, Huang QS (1984) Isolation and structure of neo-gambogic acid from Gamboge. Acta Pharmacol Sin 19:636-639
5. Qu BX, Hao XG, Li DH (1991) The experimental study on antineoplastic action of Gambogic-II. Chin J Clin Oncol 18:50-52
6. Li QL, Cheng H, Zhu GQ, Yang L, Zhou A, Wang XS, Fang NB, Xia LZ, Su JJ, Wang M, Peng DY, Xu Q (2010) Gambogenic acid inhibits proliferation of A549 cells through apoptosisinducing and cell cycle arresting. Biol Pharm Bull 33:415-420
7. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40:151-160 (Pubitemid 29010168)
8. Postma TJ, van Groeningen CJ, Witjes RJ, Weerts JG, Kralendonk JH, Heimans JJ (1998) Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38:69-75 (Pubitemid 28107894)
9. Neyns B, Sadones J, Chaskis C, De Ridder M, Keyaerts M, Veld PI, Michotte A (2005) The role of chemotherapy in the treatment of low-grade glioma. A review of the literature. Acta Neurol Belg 105:137-143 (Pubitemid 41479698)
10. Perilongo G (2005) Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low-grade glioma. J Neurooncol 75:301-307 (Pubitemid 43019485)
11. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM (2009) Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 29:5171-5184
12. Koul D (2008) PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7:1321-1325
13. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/ Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5:234-248 (Pubitemid 36132805)
14. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710 (Pubitemid 350070717)
15. Cheng CK, Fan QW, Weiss WA (2009) PI3K signaling in glioma- animal models and therapeutic challenges. Brain Pathol 19:112-120
16. Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89:271-277 (Pubitemid 16080782)
17. Zheng X, Rao XM, Gomez-Gutierrez JG, Hao H, McMasters KM, Zhou HS (2008) Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol 82:3415-3427 (Pubitemid 351429918)
18. Chintala SK, Tonn JC, Rao JS (1999) Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 17:495-502 (Pubitemid 29421836)
19. Jänicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase- 3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357-9360 (Pubitemid 28183012)
20. Teng DH, Hu R, Lin H, Davis T, lliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV, Steck PA (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225 (Pubitemid 27516352)
21. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G (1998) Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4:2383-2390 (Pubitemid 28477903)
22. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820-1824 (Pubitemid 29186149)
23. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-1256 (Pubitemid 32816199)
24. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122-1128 (Pubitemid 32174434)
25. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962-6970 (Pubitemid 37322983)
26. Heimberger AB, Suki D, Yang D, Shi W, Aldape K (2005) The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3:38
27. Lucibello FC, Sewing A, Brüsselbach S, Bürger C, Müller R (1993) Deregulation of cyclins D1 and E and suppression of cdk2 and cdk4 in senescent human fibroblasts. J Cell Sci 105:123-133 (Pubitemid 23187552)
28. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624